eClic

BrickBio is a biotechnology company specializing in site-specific bioconjugation to develop next-generation biologics and protein therapeutics. The company utilizes its proprietary eCLIC™ (Electrochemical Protein Labeling) platform, a rapid and scalable conjugation chemistry that enables precise modification of proteins, including therapeutic antibodies and cytokines. By incorporating unnatural amino acids at specific sites, BrickBio creates novel antibody-drug conjugates (ADCs) and protein-protein conjugates with optimized efficacy, half-life, and safety profiles. The technology is designed to overcome traditional hurdles in bioconjugation, offering a versatile toolkit for both eukaryotic and prokaryotic expression systems.